Redefine staff productivity with a fully integrated, automated molecular platform
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
The BD MAX™ System is designed to help address today’s challenges, while preparing your laboratory for tomorrow’s possibilities with a broad and expanding suite of assays, while also providing open-system flexibility for users to design and run their own assays.1
The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in approximately 3 hours*
*Assay times may vary
The BD MAX™ Enteric Solutions offer targeted syndromic panels that provide timely and accurate detection of the most common bacterial, viral and parasitic pathogens responsible for infectious diarrhea.2,3,4
Acute infectious gastroenteritis (AGE) challenges the healthcare system. There is a high incidence of AGE in the U.S. and it is a common reason for outpatient visits and hospitalizations, with approximately 179 million cases per year5 and 128,000 hospitalizations per year.6
Conventional methods used to detect agents of AGE infections such as culture, microscopy, and immunoassays come with disadvantages:
This can lead to less effective clinical decision-making and result in:12
The system provides highly sensitive and specific results through real-time PCR technology, and consistent results through standardized workflow and protocols.
Catalog number: 442963
Extends testing coverage to lower-prevalence bacterial pathogens.16
Catalog number: 443812
Detects 3 commonly isolated and highly pathogenic parasites that cause gastroenteritis.17
Catalog number: 442960
Broad coverage of key viral pathogens – Norovirus, Rotavirus, Adenovirus (40/41), Sapovirus, and Human Astrovirus.18
Catalog number: 443985
While progress has been made in the fight against healthcare-associated infections (HAIs), they are still among the leading threats to patient safety. HAIs affect one out of every 31 hospital patients at any one time. Over 1,000,000 HAIs occur across the U.S. healthcare system every year, leading to the loss of tens of thousands of lives and adding billions of dollars to healthcare costs.19
By combining early and accurate detection of HAIs with appropriate infection control interventions and patient treatment, we can prevent transmission, improve patient management and reduce the financial burden on healthcare systems.20
BD has deep history in microbiology—from plated media to molecular diagnostics—demonstrating our unique strength in helping hospitals manage the spread of infections.
BD offers a comprehensive suite of molecular solutions designed to detect healthcare-associated infections on the BD MAX™ System. Molecular testing is highly sensitive and provides a faster result compared to culture methods, which can aid in more effective infection control measures.21,22
The BD MAX System™ delivers automated extraction, amplification and detection of the most common HAIs, with up to 24 patient results in approximately 3 hours.
The BD MAX™ Cdiff assay is a test for the detection of the Clostridioides difficile toxin B gene (tcdB) in liquid or soft stool from patients suspected of having Clostridioides difficile infection (CDI). The assay provides a highly accurate result in an actionable timeframe and requires limited hands-on time as compared to traditional methods.23
Catalog number: 443418
The BD MAX™ MRSA XT Panel is a screening test for nasal carriage of MRSA aiding in transmission prevention and infection control. The assay provides comprehensive coverage including detection of 11 MREJ genotypes representing most of mecA and mecC harboring MRSA strains in addition to mecA and mecC gene drop-out mutants.
Catalog number: 443461
The BD MAX™ StaphSR Panel is a pre-surgical screening test for nasal carriage of Staphylococcus aureus or MRSA aiding in transmission prevention and infection control. The assay offers the same level of comprehensive coverage as the BD MAXTM MRSA XT assay, including detection of 11 MREJ genotypes representing most of mecA and mecC harboring MRSA strains in addition to mecA and mecC gene drop-out mutants.24
Catalog number: 443419
The BD MAX™ CPO assay is intended as an aid to infection control in the detection of carbapenem-non-susceptible bacteria that colonize patients in healthcare settings. The assay is designed for the detection and differentiation of the carbapenemase genes blaKPC, blaNDM, blaVIM/blaIMP and blaOXA-48, that are associated with carbapenem non-susceptibility in gram-negative bacteria.25
Catalog number: 445262
Vaginitis/Vaginosis, STIs, and antepartum
Clinicians and laboratories are faced with increasing challenges in managing workload and patient needs when it comes to reproductive health. Staggering costs to the U.S. healthcare system caused by the growing number of new infections demand action in the way we test for sexually-transmitted infections (STIs).26 For vaginal infections, traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.27 Visit our women’s health solutions site to learn more about the BD Women’s Health portfolio of products.
The BD Vaginal Panel is the first FDA market-authorized, microbiome-based, polymerase chain reaction (PCR) assay that directly detects the 3 most common infectious causes of vaginitis: Bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis.28
With the BD Vaginal Panel, you can maximize efficiency with 1 collection, 1 test for the 3 most common infectious causes of vaginitis. This assay separately reports Candida krusei and Candida glabrata, which may assist clinicians in choosing the appropriate antimicrobial therapy for their patients.29
The BD Vaginal Panel is the first FDA market-authorized, microbiome-based, polymerase chain reaction (PCR) assay that directly detects the 3 most common infectious causes of vaginitis: Bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis.28
With the BD Vaginal Panel, you can maximize efficiency with 1 collection, 1 test for the 3 most common infectious causes of vaginitis. This assay separately reports Candida krusei and Candida glabrata, which may assist clinicians in choosing the appropriate antimicrobial therapy for their patients.29
Catalog number: 443712
The BD CTGCTV2 for BD MAX™ System is designed to detect the 3 most prevalent non-viral sexually transmitted infections - Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) - in a single assay. With the BD CTGCTV2 for BD MAX™ System you can provide quality patient care and support clinical decision accuracy and patient management.30
Catalog number: 443904
The BD MAX™ GBS assay is a fully-automated, real-time PCR method for the detection of GBS from enriched culture. It simplifies detection of GBS colonization in antepartum pregnant women, and rapidly identifies Group B Streptococcus after an overnight Lim Broth enrichment.31
Catalog number: 441772
SARS-CoV-2, Influenza (flu), and respiratory syncytial virus (RSV) are 3 different viral respiratory infections that often present with overlapping signs and symptoms. Ensuring accurate diagnosis and treatment for these conditions can be extremely difficult without access to testing.32,33
Testing can help better ensure accurate diagnosis and rule out possibilities of co-infection. It may also reduce community transmission, improve disease surveillance efforts, and better inform patient treatment and management decisions. This is especially critical for patients at higher-risk of severe infection such as the elderly, young children, and those with co-infections, or certain pre-existing medical conditions.30,31,34,35
With the BD Respiratory Viral Panel for BD MAX™ System, you can simultaneously detect and differentiate SARS-CoV-2, influenza A, influenza B and/or RSV from one sample. 36
Catalog number: 445373
The BD SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal, anterior nasal, mid-turbinate, and oropharyngeal swab specimens as well as nasopharyngeal wash/aspirate or nasal aspirate specimens obtained from any individuals, including individuals without symptoms or other reasons to suspect COVID-19.41
Catalog number: 44500301
Disclaimer for the BD SARs-CoV-2 Reagents for BD MAX System: This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
The BD MAX™ Open System Reagents allow you to create your own lab-developed tests or run third party assays to address emerging diagnostic demands and meet local healthcare needs. BD offers an array of nucleic acid extraction and amplification reagents for use on the BD MAX™ System.
Assays available for BD MAX™ system
MAX PERFORMANCE
Improve patient care with speed and accuracy*
MAX EFFICIENCY
Improve your laboratory’s productivity with a streamlined and standardized workflow
MAX VERSATILITY
Improve your laboratory with clinically relevant and differentiated menu offerings
*As compared to traditional methods
